Human cytomegalovirus terminase inhibitors letermovir, tomeglovir, and the halogenated benzimidazoles modify DNA cleavage/packaging to generate a super-genomic DNA species by cleavage site skipping
- 20 May 2026
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 251, 106446
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science, ICT and Future Planning
- Merck Sharp and Dohme K.K.
- MSD Sharp and Dohme (53560)
- School of Medicine, Virginia Commonwealth University
- National Cancer Institute
This publication has 25 references indexed in Scilit:
- Substitution-inert polynuclear platinum compounds inhibit human cytomegalovirus attachment and entryAntiviral Research, 2020
- Cryo-EM structures of herpes simplex virus type 1 portal vertex and packaged genomeNature, 2019
- A third component of the human cytomegalovirus terminase complex is involved in letermovir resistanceAntiviral Research, 2017
- Herpesvirus Capsid Assembly and DNA Packaging2017
- Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovirAntiviral Research, 2013
- A human cytomegalovirus deleted of internal repeats replicates with near wild type efficiency but fails to undergo genome isomerizationVirology, 2010
- Antiviral drugs for cytomegalovirus diseasesAntiviral Research, 2006
- Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatmentsThe Lancet Infectious Diseases, 2004
- Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of actionJournal of Antimicrobial Chemotherapy, 2001
- Tetracycline-Mediated Regulation of Gene Expression within the Human Cytomegalovirus GenomeVirology, 1999